18 - World Journal of Gastroenterology
18 - World Journal of Gastroenterology
18 - World Journal of Gastroenterology
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2566 ISSN 1007-9327 CN 14-1219/R <strong>World</strong> J Gastroenterol May 14, 2007 Volume 13 Number <strong>18</strong><br />
Pichoud C, Villet S, Trepo C, Zoulim F. Resistance <strong>of</strong> human<br />
hepatitis B virus to reverse transcriptase inhibitors: from<br />
genotypic to phenotypic testing. J Clin Virol 2005; 34 Suppl 1:<br />
S34-S43<br />
1<strong>18</strong> Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch<br />
P, Rubin R, Bourliere M, Kowdley K, Trepo C, Gray Df D,<br />
Sullivan M, Kleber K, Ebrahimi R, Xiong S, Brosgart CL.<br />
Adefovir dipivoxil alone or in combination with lamivudine<br />
in patients with lamivudine-resistant chronic hepatitis B.<br />
<strong>Gastroenterology</strong> 2004; 126: 91-101<br />
119 Manolakopoulos S, Bethanis S, Koutsounas S, Goulis<br />
J, Saverriadis A, Xristias E, Christidou A, Pavlidis C,<br />
Toubanakis C, Vlachogiannakos J, Triantos C, Avgerionos<br />
A, Tzourmakliotis D. Adefovir alone or combination with<br />
lamivudine in patients with lamivudine-resistance chronic<br />
HBeAg-negative heptitis B. A non randomized multicenter<br />
controlled trial. Hepatology 2005; 42 Suppl 2: 592A-593A<br />
120 Barbon V, Marzano A, Carenzi S, Lagget M, Aleesandria C,<br />
Olivero A, Gaia S, Ciancio A, Smedile A, Rizetto M. Treatment<br />
with adefovir alone or in combination with lamivudine in<br />
chronic hepatitis B lamivudine resistant patients: results after<br />
two years. J Hepatology 2006; 44 Suppl 2: S178-S179<br />
121 Lada O, Benhamou Y, Cahour A, Katlama C, Poynard T,<br />
Thibault V. In vitro susceptibility <strong>of</strong> lamivudine-resistant<br />
hepatitis B virus to adefovir and ten<strong>of</strong>ovir. Antivir Ther 2004; 9:<br />
353-363<br />
122 Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF,<br />
Carrilho FJ, Omata M. The polymerase L528M mutation<br />
cooperates with nucleotide binding-site mutations, increasing<br />
hepatitis B virus replication and drug resistance. J Clin Invest<br />
2001; 107: 449-455<br />
123 Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WE<br />
4th. Cross-resistance testing <strong>of</strong> next-generation nucleoside<br />
and nucleotide analogues against lamivudine-resistant HBV.<br />
Antivir Ther 2005; 10: 625-633<br />
124 Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang<br />
CN, Barker KF. A double-blind randomized trial <strong>of</strong> adefovir<br />
dipivoxil in Chinese subjects with HBeAg-positive chronic<br />
hepatitis B. Hepatology 2006; 44: 108-116<br />
125 Lee Y, Chung Y, Ryu SH, Kim JA, Choi MH, Jung SW, Kim<br />
SH, Shin JW, Kim KM, Lim YS, Lee YS. Hepatitis B virus with<br />
rtL80V/I mutation associates with poor response to adefovir<br />
dipivoxil therapy. Hepatology 2005; 42 Suppl 1: 575A<br />
126 Liu CJ, Kao JH, Chen PJ, Chen TC, Lin FY, Lai MY, Chen<br />
DS. Overlap lamivudine treatment in patients with chronic<br />
hepatitis B receiving adefovir for lamivudine-resistant viral<br />
mutants. J Viral Hepat 2006; 13: 387-395<br />
127 Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer<br />
SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P,<br />
Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner<br />
N, Locarnini S, Colonno RJ. Clinical emergence <strong>of</strong> entecavirresistant<br />
hepatitis B virus requires additional substitutions<br />
in virus already resistant to Lamivudine. Antimicrob Agents<br />
Chemother 2004; 48: 3498-3507<br />
128 Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R,<br />
Weinheimer S, Colonno RJ. Efficacies <strong>of</strong> entecavir against<br />
lamivudine-resistant hepatitis B virus replication and<br />
recombinant polymerases in vitro. Antimicrob Agents Chemother<br />
2002; 46: 2525-2532<br />
129 Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF,<br />
Cianciara J, Boron-Kaczmarska A, Martin P, Goodman Z,<br />
Colonno R, Cross A, Denisky G, Kreter B, Hindes R. Entecavir<br />
for treatment <strong>of</strong> lamivudine-refractory, HBeAg-positive<br />
chronic hepatitis B. <strong>Gastroenterology</strong> 2006; 130: 2039-2049<br />
130 Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Klesczewski<br />
K, Tenney D. Assessment at three years shows high barrier to<br />
resistance is maintained in entecavir-treated nucleoside naïve<br />
patients while resistance emergence increases over time in<br />
lamivudine refractory patients. Hepatology 2006; 44 Suppl 1:<br />
229A-230A<br />
131 de Vries-Sluijs TE, van der Eijk AA, Hansen BE, Osterhaus<br />
AD, de Man RA, van der Ende ME. Wild type and YMDD<br />
variant <strong>of</strong> hepatitis B virus: no difference in viral kinetics<br />
www.wjgnet.com<br />
on lamivudine/ten<strong>of</strong>ovir therapy in HIV-HBV co-infected<br />
patients. J Clin Virol 2006; 36: 60-63<br />
132 Hann HW, Chae HB, Dunn SR. Ten<strong>of</strong>ovir (TNV) has<br />
stronger antiviral effect than adefovir dipivoxil (ADV)<br />
against lamivudine (LAM) resistant hepatitis B virus (HBV). J<br />
Hepatology 2006; 44 Suppl 2: S<strong>18</strong>4-S<strong>18</strong>5<br />
133 Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M,<br />
Tacke F, Nunez M, Mauss S, Lutz T, Klausen G, Locarnini S,<br />
Soriano V. Selection <strong>of</strong> hepatitis B virus polymerase mutations<br />
in HIV-coinfected patients treated with ten<strong>of</strong>ovir. Antivir Ther<br />
2005; 10: 727-734<br />
134 Mauss S, Nelson M, Lutz T, Sheldon J, Bruno R, Bömmel vF,<br />
Rockstroh JK, Wolf E, Stoehr A, Soriano V, Berger F, Berg<br />
T, Carlebach A, Schwarze-Zander C, Wunsche T, Jaeger H,<br />
Schmutz G. First line combination therapy <strong>of</strong> chronic hepatitis<br />
B with ten<strong>of</strong>ovir plus lamivudine versus sequential therapy<br />
with ten<strong>of</strong>ovir therapy after lamivudine failure. Hepatology<br />
2005; 42 Suppl 1: 574A-575A<br />
135 Brunelle MN, Jacquard AC, Pichoud C, Durantel D, Carrouee-<br />
Durantel S, Villeneuve JP, Trepo C, Zoulim F. Susceptibility to<br />
antivirals <strong>of</strong> a human HBV strain with mutations conferring<br />
resistance to both lamivudine and adefovir. Hepatology 2005;<br />
41: 1391-1398<br />
136 Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C,<br />
Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz<br />
A, Locarnini S. Resistance to adefovir dipivoxil therapy<br />
associated with the selection <strong>of</strong> a novel mutation in the HBV<br />
polymerase. <strong>Gastroenterology</strong> 2003; 125: 292-297<br />
137 Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A,<br />
Keeffe EB, Hussain M, Cursaro C, Richtmyer P, Marrero JA,<br />
Lok AS. Adefovir-resistant hepatitis B can be associated with<br />
viral rebound and hepatic decompensation. J Hepatol 2005; 43:<br />
937-943<br />
138 Delaney WE 4th, Ray AS, Yang H, Qi X, Xiong S, Zhu Y, Miller<br />
MD. Intracellular metabolism and in vitro activity <strong>of</strong> ten<strong>of</strong>ovir<br />
against hepatitis B virus. Antimicrob Agents Chemother 2006; 50:<br />
2471-2477<br />
139 Villeneuve J, Willems B, Zoulim F. Efficacy <strong>of</strong> ten<strong>of</strong>ovir in<br />
patients with chronic hepatitis B and resistance or sub-optimal<br />
response to adefovir. Hepatology 2005; 42 Suppl 1: 588A<br />
140 Villet V, Pichoud C, Ollivet A, Villeneuve J, Trepo C, Zoulim F.<br />
Sequential antiviral therapy leads to the emergence <strong>of</strong> multiple<br />
drug resistant hepatitis B virus. Hepatology 2005; 42 Suppl 1:<br />
581A<br />
141 Marshall E. A shadow falls on hepatitis B vaccination effort.<br />
Science 1998; 281: 630-631<br />
142 Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM,<br />
Brodovicz K, Walker AM. Hepatitis B vaccination and the risk<br />
<strong>of</strong> multiple sclerosis. N Engl J Med 2001; 344: 327-332<br />
143 Confavreux C, Suissa S, Saddier P, Bourdes V, Vukusic S.<br />
Vaccinations and the risk <strong>of</strong> relapse in multiple sclerosis.<br />
Vaccines in Multiple Sclerosis Study Group. N Engl J Med<br />
2001; 344: 319-326<br />
144 Jefferson T, Demicheli V. No evidence that vaccines cause<br />
insulin dependent diabetes mellitus. J Epidemiol Community<br />
Health 1998; 52: 674-675<br />
145 Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC,<br />
Lauder IJ, Ng CP, Chung HT. A controlled trial <strong>of</strong> interferon<br />
with or without prednisone priming for chronic hepatitis B.<br />
<strong>Gastroenterology</strong> 1992; 102: 2091-2097<br />
146 Brook MG, Karayiannis P, Thomas HC. Which patients with<br />
chronic hepatitis B virus infection will respond to alphainterferon<br />
therapy? A statistical analysis <strong>of</strong> predictive factors.<br />
Hepatology 1989; 10: 761-763<br />
147 Hui CK, Lai LS, Lam P, Zhang HY, Fung TT, Lai ST, Wong<br />
WM, Lo CM, Fan ST, Leung N, Lau GK. 48 weeks pegylated<br />
interferon alpha-2a is superior to 24 weeks <strong>of</strong> pegylated<br />
interferon alpha-2b in achieving hepatitis B e antigen<br />
seroconversion in chronic hepatitis B infection. Aliment<br />
Pharmacol Ther 2006; 23: 1171-1178<br />
148 Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm<br />
SW, Heathcote EJ, Brown NA, Atkins M, Woessner M,<br />
Gardner SD. Predictors <strong>of</strong> HBeAg loss after lamivudine